ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Dr. Lal Path Labs' subsidiary completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana, for Rs.38.00 Crore. The target is now a subsidiary.
Dr. Lal PathLabs' subsidiary, DLPL Dubai, completed the acquisition of an 80% stake in Sunshine Healthcare Limited, Ghana. Sunshine Healthcare is now a step-down subsidiary.
Dr. Lal PathLabs will hold a board meeting on November 04, 2026, to consider and approve standalone and consolidated financial results for the quarter ending September 30, 2026.
Designated persons and the company's Employee Welfare Trust disclosed multiple equity transactions, including ESOP exercises and market sales, in a recent regulatory filing.
Dr. Lal Path Labs Ltd. will acquire a 70% stake in SN Genelab Private Limited for Rs. 168 Crore to strengthen its genomics diagnostics portfolio.
Dr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited for a total consideration of up to ₹199.5 Crore.
Dr. Lal PathLabs discloses share transactions by designated persons and an employee welfare trust under PIT regulations.
Designated persons at Dr. Lal PathLabs Ltd disclosed three equity trades totaling Rs. 0.50 Crore, as mandated under Insider Trading regulations.
Designated persons of Dr. Lal PathLabs Ltd sold equity shares worth a combined ₹0.49 Crore via market sales.
Designated persons and the employee welfare trust of Dr. Lal PathLabs Ltd disclosed share transactions under PIT Regulations. These trades involve ESOP-related activities and market sales.